Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2026 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc....
April 09, 2026 08:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) --...
April 08, 2026 08:40 ET | Source: Autonomix Medical, Inc.

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

THE WOODLANDS, TX, April 08, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted...
April 08, 2026 07:47 ET | Source: Curanex Pharmaceuticals Inc

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple...
April 02, 2026 11:55 ET | Source: Research and Markets

Global Interventional Oncology Industry Set to Grow by $1.18 Billion During 2026-2030 - AI-Assisted Imaging and Minimally Invasive Procedures Drive Interventional Oncology Expansion

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market...
April 02, 2026 11:51 ET | Source: Research and Markets

Global Tumor Models Market Set to Soar from $2.37B in 2026 to $3.57B by 2030 - 3D Spheroids and Organ-on-a-Chip Propel Tumor Model Advancements

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Models Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor models market has been experiencing rapid growth,...
April 02, 2026 11:31 ET | Source: Research and Markets

Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the Industry

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Microenvironment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor microenvironment (TME) market has...
March 31, 2026 09:15 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced...
March 30, 2026 05:51 ET | Source: Research and Markets

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pancreatic adenocarcinoma...
March 30, 2026 05:37 ET | Source: Research and Markets

Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated...